Effect of Varying Levels of Disease Management on Smoking Cessation: A Randomized Trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cigarette smoking is a chronic, relapsing illness that is inadequately addressed in primary care practice. OBJECTIVE: To compare cessation rates among smokers who receive pharmacotherapy alone or combined with either moderate- or high-intensity disease management that includes counseling and provider feedback. DESIGN: Randomized clinical trial from June 2004 to December 2007. SETTING: 50 rural primary care practices. PARTICIPANTS: 750 persons who smoke more than 10 cigarettes per day. INTERVENTION: Pharmacotherapy alone (n = 250), pharmacotherapy supplemented with up to 2 counseling calls (moderate-intensity disease management) (n = 249), or pharmacotherapy supplemented with up to 6 counseling calls (high-intensity disease management) (n = 251). Interventions were offered every 6 months for 2 years. All participants were offered free pharmacotherapy. Moderate-intensity and high-intensity disease management recipients had postcounseling progress reports faxed to their physicians. MEASUREMENTS: Self-reported, point-prevalence smoking abstinence at 24 months (primary outcome) and overall (0 to 24 months) analyses of smoking abstinence, utilization of pharmacotherapy, and discussions about smoking with physicians (secondary outcomes). Research assistants who were blinded to treatment assignment conducted outcome assessments. RESULTS: Pharmacotherapy utilization was similar across treatment groups, with 473 of 741 (63.8%), 302 of 739 (40.9%), 175 of 732 (23.9%), and 179 of 726 (24.7%) participants requesting pharmacotherapy during the first, second, third, and fourth 6-month treatment cycles, respectively. Of participants who saw a physician during any given treatment cycle, 37.5% to 59.5% reported that they had discussed smoking cessation with their physician; this did not differ across the treatment groups. Abstinence rates increased throughout the study, and overall (0 to 24 months) analyses demonstrated higher abstinence among the high-intensity disease management group than the moderate-intensity disease management group (odds ratio [OR], 1.43 [95% CI, 1.00 to 2.03]) and among the combined disease management groups than the pharmacotherapy-alone group (OR, 1.47 [CI, 1.08 to 2.00]). Self-reported abstinence at 24 months was 68 of 244 (27.9%) and 56 of 238 (23.5%) participants in the high- and moderate-intensity disease management groups, respectively (OR, 1.33 [CI, 0.88 to 2.02]), and 56 of 244 (23.0%) participants in the pharmacotherapy-alone group (OR, 1.12 [CI, 0.78 to 1.61] for combined disease management vs. pharmacotherapy alone). LIMITATION: The effect of pharmacotherapy management cannot be separated from the provision of free pharmacotherapy, and cessation was validated in only 58% of self-reported quitters. CONCLUSION: Smokers are willing to make repeated pharmacotherapy-assisted quit attempts, leading to progressively greater smoking abstinence. Although point-prevalence abstinence did not differ at 24 months, analyses that incorporated assessments across the full 24 months of treatment suggest that higher-intensity disease management is associated with increased abstinence. PRIMARY FUNDING SOURCE: National Cancer Institute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating the public health impact of health promotion interventions: the RE-AIM framework.
Glasgow, R. E., Vogt, T. M., & Boles, S. M. (1999) · American Journal of Public Health · doi:10.2105/ajph.89.9.1322 · Cited by 7,217 · cited 2×
“Providing treatment only to smokers who are already prepared to quit further limits the reach of current smoking cessation interventions (2).”
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800
Gonzales, D. H., Nides, M. A., Ferry, L. H., Kustra, R. P., Jamerson, B. D., Segall, N., Herrero, L. A., Krishen, A., Sweeney, A., Buaron, K., et al. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115750 · Cited by 143
Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers
Gourlay, S. G., Forbes, A., Forbes, A., Marriner, T., Pethica, D., & McNeil, J. J. (1995) · BMJ · doi:10.1136/bmj.311.7001.363 · Cited by 104
Shiffman, S., Dresler, C. M., & Rohay, J. M. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00576.x · Cited by 54
Recycling with nicotine patches in smoking cessation
TØNNESEN, P., NØRREGAARD, J., SÄWE, U., & SIMONSEN, K. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02060.x · Cited by 48 · cited 1×
“Although small early studies of relapsing smokers were discouraging (28, 29), larger studies have demonstrated that active treatment of relapsed smokers with transdermal nicotine patch (30), nicotine lozenge (31), or bupropion (32) is associated with higher cessation rates.”
Cited by
Telephone counselling for smoking cessation
Stead, L. F., Hartmann-Boyce, J., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002850.pub3 · Cited by 1,003
Combined pharmacotherapy and behavioural interventions for smoking cessation
Stead, L. F., Koilpillai, P., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008286.pub3 · Cited by 829
US Preventive Services Task Force, Krist, A. H., Davidson, K. W., Mangione, C. M., Barry, M. J., Cabana, M., Caughey, A. B., Donahue, K., Doubeni, C. A., Epling, J. W., et al. (2021) · JAMA · doi:10.1001/jama.2020.25019 · Cited by 512
Motivational interviewing for smoking cessation
Lindson-Hawley, N., Thompson, T. P., & Begh, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006936.pub3 · Cited by 386
Motivational interviewing for smoking cessation
Lindson, N., Thompson, T. P., Ferrey, A., Lambert, J. D., & Aveyard, P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006936.pub4 · Cited by 191
Metadata
- Authors
- Ellerbeck, E. F., Mahnken, J. D., Cupertino, A. P., Cox, L. S., Greiner, K. A., Mussulman, L. M., Nazir, N., Shireman, T. I., Resnicow, K., & Ahluwalia, J. S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-04-07
- Volume
- 150
- Issue
- 7
- Pages
- 437-446
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2036401279
- Cited by
- 78
- References
- 8
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Varying Levels of Disease Management on Smoking Cessation: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-150-7-200904070-00003
- The paper
- Ellerbeck, E. F., Mahnken, J. D., Cupertino, A. P., Cox, L. S., Greiner, K. A., Mussulman, L. M., Nazir, N., Shireman, T. I., Resnicow, K., & Ahluwalia, J. S. (2009). Effect of Varying Levels of Disease Management on Smoking Cessation: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-150-7-200904070-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.